DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.
Bleomycin
/ pharmacology
Bronchi
/ cytology
Cell Line, Tumor
Cell Transformation, Neoplastic
/ genetics
DNA Methylation
DNA Repair
DNA-Activated Protein Kinase
/ genetics
Epigenesis, Genetic
Epithelial Cells
/ drug effects
Haploinsufficiency
Humans
Promoter Regions, Genetic
Respiratory Mucosa
/ metabolism
DNA repair capacity
DNA-PKc
Epigenome
Lung cancer
Pre-malignancy
Journal
DNA repair
ISSN: 1568-7856
Titre abrégé: DNA Repair (Amst)
Pays: Netherlands
ID NLM: 101139138
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
25
02
2019
revised:
11
04
2019
accepted:
13
04
2019
pubmed:
6
5
2019
medline:
12
2
2020
entrez:
6
5
2019
Statut:
ppublish
Résumé
The expression of DNA-dependent protein kinase catalytic subunit (DNA-PKc) is highly variable in smokers and reduced enzyme activity has been associated with risk for lung cancer. An in vitro model of lung pre-malignancy was used to evaluate the role of double-strand break DNA repair capacity in transformation of hTERT/CDK4 immortalized human bronchial epithelial cells (HBECs) and reprograming of the epigenome. Here we show that knockdown of DNA-PKc to levels simulating haploinsufficiency dramatically reduced DNA repair capacity following challenge with bleomycin and significantly increased transformation efficiency of HBEC lines exposed weekly for 12 weeks to this radiomimetic. Transformed HBEC lines with wild type or knockdown of DNA-PKc showed altered expression of more than 1,000 genes linked to major cell regulatory pathways involved in lung cancer. While lung cancer driver mutations were not detected in transformed clones, more than 300 genes that showed reduced expression associated with promoter methylation in transformed clones or predictive for methylation in malignant tumors were identified. These studies support reduced DNA repair capacity as a key factor in the initiation and clonal expansion of pre-neoplastic cells and double-strand break DNA damage as causal for epigenetic mediated silencing of many lung cancer-associated genes. The fact that DNA damage, repair, and epigenetic silencing of genes are causal for many other cancers that include colon and prostate extends the generalizability and impact of these findings.
Identifiants
pubmed: 31055244
pii: S1568-7864(19)30061-8
doi: 10.1016/j.dnarep.2019.04.006
pmc: PMC6551272
mid: NIHMS1528745
pii:
doi:
Substances chimiques
Bleomycin
11056-06-7
DNA-Activated Protein Kinase
EC 2.7.11.1
PRKDC protein, human
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Subventions
Organisme : NCI NIH HHS
ID : P30 CA118100
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES015262
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180950
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233259
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1345-50
pubmed: 15668400
Cancer Res. 1990 Mar 1;50(5):1613-9
pubmed: 1689213
Clin Exp Dermatol. 2013 Oct;38(7):787-90
pubmed: 24073657
J Thorac Cardiovasc Surg. 1994 Feb;107(2):590-5
pubmed: 7905543
Am J Pathol. 1994 Feb;144(2):296-302
pubmed: 7906095
DNA Repair (Amst). 2009 Aug 6;8(8):920-9
pubmed: 19535303
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Acta Biochim Biophys Sin (Shanghai). 2016 Jul;48(7):603-16
pubmed: 27217472
Carcinogenesis. 2004 Jun;25(6):1063-7
pubmed: 14742312
Cancer Lett. 2007 May 8;249(2):178-87
pubmed: 16971039
Cell Res. 2008 Jan;18(1):114-24
pubmed: 18166980
Cancer Cytopathol. 2013 Sep;121(9):500-7
pubmed: 23495083
Mutat Res. 2015 Mar;773:48-62
pubmed: 25847421
Cancer Lett. 2018 Sep 1;431:230-243
pubmed: 29111349
Oncogene. 2002 Feb 7;21(7):1048-61
pubmed: 11850822
Cancer Res. 2003 Aug 15;63(16):4842-8
pubmed: 12941804
J Natl Cancer Inst. 2014 Jan;106(1):djt356
pubmed: 24309006
Cancer Res. 1989 Oct 1;49(19):5305-11
pubmed: 2670201
Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):8905-9
pubmed: 15956212
Annu Rev Physiol. 2015;77:453-74
pubmed: 25668024
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Cancer Res. 2008 Apr 15;68(8):3049-56
pubmed: 18413776
Mol Cell Biol. 1999 Nov;19(11):7681-7
pubmed: 10523656
Oncotarget. 2017 Dec 17;9(13):11414-11426
pubmed: 29541423
Clin Cancer Res. 2012 Jun 15;18(12):3387-95
pubmed: 22510351
Cancer Cell. 2017 Sep 11;32(3):360-376.e6
pubmed: 28898697
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
Cancer Res. 2008 Nov 1;68(21):9005-14
pubmed: 18974146
Nat Rev Cancer. 2008 Mar;8(3):193-204
pubmed: 18256616
J Biol Chem. 2007 Mar 2;282(9):6582-7
pubmed: 17189255
Science. 2001 Aug 10;293(5532):1089-93
pubmed: 11498579
Cell. 1992 Nov 27;71(5):865-73
pubmed: 1423634
Carcinogenesis. 2009 Jul;30(7):1132-8
pubmed: 19435948
Cytometry A. 2009 Oct;75(10):840-7
pubmed: 19658174
Semin Cancer Biol. 2015 Dec;35 Suppl:S5-S24
pubmed: 25869442
Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13710-5
pubmed: 21807998
Australas J Dermatol. 2012 Feb;53(1):61-5
pubmed: 22309335
Carcinogenesis. 2001 May;22(5):723-7
pubmed: 11323390
PLoS Genet. 2007 Jul;3(7):e110
pubmed: 17616978
PLoS Genet. 2008 Aug 15;4(8):e1000155
pubmed: 18704159
Int J Cancer. 2003 Oct 20;107(1):84-8
pubmed: 12925960
Cancer Res. 2010 Jan 15;70(2):568-74
pubmed: 20068159
J Biol Chem. 2005 Apr 15;280(15):14709-15
pubmed: 15677476
Acta Derm Venereol. 2005;85(5):394-9
pubmed: 16159729
Oncol Rep. 2018 Mar;39(3):912-920
pubmed: 29344644
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
Cancer Res. 2011 Apr 15;71(8):3087-97
pubmed: 21363915
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Oncogene. 2015 Jan 29;34(5):621-30
pubmed: 24469050
J Mol Diagn. 2011 Jan;13(1):74-84
pubmed: 21227397
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6
pubmed: 9751761